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Objectives: Gd-EOB-DTPA (gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid) is a
gadolinium-based hepatocyte-specific contrast agent for magnetic resonance imaging (MRI). The aim of
this study was to determine whether the hepatic uptake and excretion of Gd-EOB-DTPA differ between
patients with primary biliary cirrhosis (PBC) and healthy controls, and whether differences could be
quantified.
Methods: Gd-EOB-DTPA-enhanced liver MRI was performed in 20 healthy volunteers and 12 patients
with PBC. The uptake of Gd-EOB-DTPA was assessed using traditional semi-quantitative parameters
(Cmax, Tmax and T1/2), as well as model-free parameters derived after deconvolutional analysis (hepatic
extraction fraction [HEF], input-relative blood flow [irBF] and mean transit time [MTT]). In each individual,
all parameters were calculated for each liver segment and the median of the segmental values was used
to define a global liver median (GLM).
Results: Although the PBC patients had relatively mild disease according to their Model for End-stage
Liver Disease (MELD), Child–Pugh and Mayo risk scores, they had significantly lower HEF and shorter
MTT values compared with the healthy controls. These differences significantly increased with increasing
MELD and Child–Pugh scores.
Conclusions: Dynamic hepatocyte-specific contrast-enhanced MRI (DHCE-MRI) has a potential role as
an imaging-based liver function test. The high spatial resolution of MRI enables hepatic function to be
assessed on segmental and sub-segmental levels.
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Introduction
For liver surgeons, postoperative liver failure is a major concern
and has become the biggest cause of postoperative mortality
after liver resection.1 The prediction of post-resection residual
liver function is currently typically based on combinations of
volumetric studies and crude assessments of global liver function,
such as the Child–Pugh score (CPS) or indocyanine green (ICG)
clearance.2,3 A more reliable liver function test, capable of evalu-
ating the status of the liver on a segmental level, whereby it would
be possible to predict remnant liver function more accurately
than with the currently available methods, would enable more
judicious decision making and would probably result in lower
postoperative mortality and morbidity. Furthermore, some liver
diseases, such as primary sclerosing cholangitis (PSC), pri-
mary biliary cirrhosis (PBC), alcoholic liver cirrhosis and even
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non-alcoholic fatty liver disease (NAFLD) affect the liver in a
non-homogeneous fashion. This makes the assessment of the
degree of liver dysfunction difficult with currently available liver
function tests (LFTs), which give a global assessment of liver func-
tion. Severe segmental or regional disease can be underdiagnosed.
A segmental liver function test requires sampling from indi-
vidual liver segments using a non-invasive, well-tolerated and
safe sampling method. Imaging-based sampling could fulfil these
criteria. Resolution should be sufficient for accurate sampl-
ing from blood vessels, parenchyma and bile ducts. This would
enable measuring of the uptake of a tracer from the bloodstream
into the parenchyma and its subsequent excretion into the bile.
Scintigraphic methods are currently the only imaging-based tests
used clinically to assess liver uptake capacity and biliary excretory
function. These methods, however, are hampered by low spatial
resolution and the limited anatomic detail obtained.4–6 This com-
plicates the accurate placement of regions of interest (ROIs),
especially in smaller structures. Computed tomography (CT) has
sufficient resolution but its use is limited by radiation, especially
when repetitive examinations are required. Magnetic resonance
imaging (MRI) has the advantage of not using ionizing irra-
diation. Gadoxetic acid or Gd-EOB-DTPA (gadolinium
ethoxybenzyl diethylenetriaminepentaacetic acid) (Primovist®;
BayerSchering Pharma AG, Berlin, Germany) is a gadolinium
chelate which is taken up by hepatocytes and excreted into the
bile.7,8 The pharmacokinetic properties of Gd-EOB-DTPA are
similar to those of the 99mTc-IDA family in that hepatocellular
uptake occurs through the organic anionic transport system
(OATS) and subsequent biliary excretion by glutathione-S-
transferase.7 Pharmacokinetic studies show that about 50% of
the administered dose of Gd-EOB-DTPA is extracted by the liver
and secreted through the hepatobiliary pathway. The remaining
50% is eliminated by renal excretion.8 Thus, hepatic uptake of
Gd-EOB-DTPA and subsequent T1-relaxation shortening are
dependent on the integrity of the hepatocyte mass. Dynamic
Gd-EOB-DTPA MRI has previously been used in animal models
for the evaluation of hepatic function in various experimental
settings, using either summary parameters or deconvolutional
analysis (DA).9–12 A method to evaluate segmental liver function,
using dynamic hepatocyte-specific contrast-enhanced MRI
(DHCE-MRI) with Gd-EOB-DTPA as tracer, has previously been
described.13
Primary biliary cirrhosis is an autoimmune liver disease, char-
acterized by the progressive destruction of intrahepatic bile
ducts, resulting in cholestasis, portal inflammation and fibrosis,
which eventually may lead to cirrhosis.14 It predominates in
females by a ratio of 9 : 1 and typically affects women aged
50–60 years.15,16 Diagnosis is based on the presence of anti-
mitochondrial antibodies (AMA) and the elevation of biochemi-
cal markers of cholestasis for a period of >6 months. Liver biopsy
is no longer mandatory for diagnosis, but aids in the work-up of
patients by excluding other causes of cholestasis.17 Furthermore,
it may give useful information on disease activity and stage.
However, the disease does not affect the liver uniformly and there
is a considerable risk for under-staging on single liver biopsies.18
The natural history of the disease is variable and ranges from
stable to rapidly progressive disease. Various attempts have been
made to predict the clinical course of patients with PBC and
several prognostic models have been developed to predict
survival.19–23 The Mayo Clinic survival model is the most widely
used of these.20,24
The aim of this study was to compare DHCE-MRI-derived
quantitative and semi-quantitative parameters in PBC patients
with those in normal controls. In patients, results were also cor-
related with the CPS, Mayo risk score and Model for End-stage
Liver Disease (MELD) score.
Materials and methods
Study subjects
Twelve patients with established diagnoses of PBC were included
in the study and 20 healthy volunteers were used as controls.
Informed consent was obtained from all participants prior to
examination and the study was approved by the Regional Ethical
Review Board. T1-weighted DHCE-MRI, using Gd-EOB-DTPA,
was performed. All subjects were instructed to fast for at least 4
hours prior to the examination. The healthy volunteers had no
history of hepatobiliary disease, previous hepatobiliary surgery or
alcohol abuse. For patients, relevant demographic and clinical
data were documented, as well as the results of LFTs from the most
recent visit documented in clinical charts. The CPS, Mayo risk
score and MELD score were calculated for each patient.
MR procedure
Data were collected using an Intera 1.5 Tesla (T) scanner (Philips
Medical Systems, Best, the Netherlands), with a four-channel
SENSE body coil (Philips Medical Systems). The whole liver
was examined using a dynamic T1-weighted three-dimensional
spoiled-gradient echo pulse sequence (repetition time/echo
time/flip angle 4.1 ms/2.0 ms/10 °, field of view = 415 mm,
matrix resolution 256 ¥ 192, 40 slices, slice thickness 10 mm,
SENSE factor R = 2). The volume was imaged in a single breath-
hold at 41 different time-points (12 s scan time per acquired
volume) and participating subjects were asked to hold their
breath at the same depth during each acquisition. Three volumes
were acquired pre-contrast for baseline calculations, followed by
38 volumes with a stepwise increase in sampling intervals up
to a total sampling time of 90 min. The sampling density
was chosen to account for the subjects’ physical capacity, data
acquisition limitations and test substance dynamics. A dose
of 0.1 ml/kg Gd-EOB-DTPA 0.25 mmol/ml was injected into
the right anterior cubital vein to coincide with the start of
the fourth acquired volume. The contrast was injected using
a power injector (Spectris MR Injector System; Medrad, Inc.,
Pittsburgh, PA, USA) at an infusion rate of 2 ml/s and was
immediately followed by a bolus of 20 ml of saline (NaCl 0.9%)
at the same infusion rate.
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Image analysis
Image analysis and subsequent calculations were performed
using in-house software written in matlab® (MathWorks, Inc.,
Novi, MI, USA). Liver response function curves were defined by
placing three ROIs in the parenchyma of each liver segment
(I–VIII), avoiding major blood vessels and visible bile ducts. The
size of the ROI was chosen arbitrarily by the investigator. The
combined relative enhancement over time of all the voxels in
the three ROIs was regarded as the parenchymal response func-
tion of that segment. Segments were anatomically defined and
the nomenclature adhered to as proposed by Strasberg.25,26
Segment IV was subdivided into IVa and IVb. The input func-
tion, representing the blood supply to the liver, used in the
deconvolution of the parenchymal response curves for calcula-
tion of the quantitative parameters, was defined by an ROI
placed in the hilar part of the portal vein. To ensure that the
input function ROI was truly representative of the portal vein
over the entire acquisition period, it was adjusted manually as
necessary. In all studies, the relative signal intensity in the ROIs
was calculated as the logarithmic ratio:
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where C(t, r) is the relative tracer concentration at time t
in voxel r, S0(r) is the mean image intensity in voxel r from the
pre-contrast images (i.e. the baseline signal intensity), and S(t, r)
is the measured image intensity in voxel r at time t. The param-
eters described below were calculated in each liver segment for all
participating subjects. In addition, a global liver median (GLM)
for each parameter was calculated using the median value of the
nine segmental parameters in each subject.
Semi-quantitative pharmacokinetic parameters
Parameters were defined as semi-quantitative when calculation
did not take into account the impact of the input function (i.e. the
amount of tracer in the circulating blood pool) on the resulting
parenchymal enhancement-over-time curve. Maximum relative
signal intensity (Cmax) and time to maximum relative signal
intensity (Tmax) were calculated directly from the parenchymal
enhancement-over-time curves. As the excretion half-time for
Gd-EOB-DTPA is much longer than the time-span used in this
study, T1/2 (time to a 50% decline in signal enhancement) was
calculated using a curve-fitting model, thus:
f k kt t= ⋅ − ⋅− ( )( ) − ( )( )1 2 T 2 TUe e1 2ln ln ,2 [Eq. 2]
where f is the fitted curve, the fitting parameters k2 and TU
describe contrast uptake, and k1 and T1/2 describe the liver contrast
excretion. The bi-exponential function is not optimal for the liver
response because, for example, it does not take into account any
contribution to signal intensity from the blood pool. Therefore,
the fit does not always converge if the whole response curve is
included; t = 240 s was selected as the starting point for the fit.
Parameters derived from deconvolutional analysis:
model-free parameters
Mathematically, the response function of an organ, in this case
the liver, can be described as a convolution between the impulse
response and the input function:
y t h t x t( ) = ( )⊗ ( ), [Eq. 3]
where y(t) is the response function, h(t) the impulse function,
x(t) the input function, and ƒ denotes the mathematical convo-
lution operator. The response function y(t) (in this case the paren-
chymal enhancement-over-time curve) and the input function
x(t) can be measured, but h(t) is unknown. However, with knowl-
edge of the input and response functions, the impulse function
can be estimated through deconvolution. From the impulse
response function curves, several functional characteristics of the
system can be derived, as has previously been described in func-
tional MRI of the kidneys.27,28 From the impulse response curve,
the hepatic extraction fraction (HEF), input-relative blood flow
(irBF) and mean transit time (MTT) were calculated. In several
studies using scintigraphy to investigate liver function, HEF has
been used as a measurement of hepatic extraction efficiency.29–35
The HEF can be described as the proportion of tracer that would
have been extracted by the liver if the tracer had entered into
the system as a short bolus without recirculation, whereas the
irBF describes the peak blood flow in an ROI relative to the peak
blood flow in the input function. The calculation of the HEF and
irBF has been extensively described in a previous publication.13
The MTT describes the mean time for a unit of the studied sub-
stance to pass through the ROI, in this case exiting through either
excretion into the bile ducts or vascular wash-out. The MTT is
calculated as the area under the impulse response curve from
peak value down to 0, divided by the peak value of the curve
(equal to the irBF).
Analysis and statistical methods
Age and gender distributions were compared using the non-
parametric Mann–Whitney U-test and the two-group pro-
portionality test, respectively. The results of the segmental
calculations and GLM were presented as summary statistics
(median and range) and compared using the Mann–Whitney
U-test. For parameters for which a significant difference in GLM
between patients and controls was observed, a test for trend across
ordered groups was used to assess the association between the
CPS and MELD score. For these calculations, the controls were
assigned dummy values of 4 for CPS, and 5 for MELD score. This
is one unit less than the lowest possible score in these models.
As the Mayo risk score was regarded as a continuous variable,
Spearman’s rank correlation was used instead, without assigning
a dummy value for the controls. In the patient group, Spearman’s
rank correlation was also used to correlate the parameters in
which a significant difference in GLM was seen, with regard to age.
Likewise, using the Mann–Whitney U-test, the outcomes of these
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parameters in the control group were compared, using gender
as the independent variable. The significance threshold was set to
a = 0.05. stata Version 10 (StataCorp LP, College Station, TX,
USA) was used for statistical analyses.
Results
Patient characteristics are shown in Table 1. Patients in the PBC
group were older than the controls (P < 0.001) and an expected
female predominance was observed (P < 0.01). Liver disease in the
patient group as a whole was mild, as can be seen in the relatively
low CPS, MELD and Mayo risk scores. The results of the segmen-
tal calculations and GLMs in the PBC patients and the normal
volunteer group are shown in Table 2. In a majority of segments,
the segmental HEF and MTT measurements were significantly
lower in PBC patients compared with normal volunteers. This was
also observed for the GLM. With the exception of one segment
(IVa), no significant differences in segmental results or GLM
were found for irBF values. The results for the semi-quantitative
parameters are shown in Table 3. No significant differences were
observed in GLM for any of these parameters. In addition,
the earliest Tmax in the PBC group for all liver segments except
segment I occurred as early as 120 s after injection of the tracer.
This means that the relative signal intensity in these segments
peaked when the intravascular bolus of the tracer passed, and that
very little tracer was subsequently extracted.
Because HEF and MTT medians differed significantly between
the patient and control groups in the majority of segmental values
as well as in the GLM, further analyses were performed to inves-
tigate the impact of disease severity on these parameters. As
Figs 1 and 2 show, MTT and HEF decreased significantly with
increasing severity of liver disease as estimated by the CPS and
MELD score, but not by the Mayo risk score (Fig. 3). In one
patient and one control, HEF, irBF and MTT values were calcu-
lated in every voxel within the liver parenchyma of one slice to give
the parametric maps presented in Fig. 4. Figure 5 shows age
plotted against HEF and MTT in PBC patients. No statistically
significant correlation was observed. In the control group, gender
was not found to be a substantial confounder. Neither the median
HEF nor the median MTT differed significantly for males and
females (P = 0.112 and P = 0.762, respectively).
Discussion
This study used PBC as a disease model to evaluate a new method
for liver function assessment. Although the number of patients in
the study was small and the group represented patients only
mildly affected by their disease, significant differences in quanti-
tative parameters measuring hepatic uptake and transport of
Gd-EOB-DTPA were found between patients and healthy con-
trols. Furthermore, a significant trend towards a decrease in these
parameters was observed as CPS and MELD score increased.
The semi-quantitative parameters were not useful in distin-
guishing between patients and normal volunteers. These param-
eters are more intuitive and easily understood than the model-free
parameters. Because they are easily accessible and do not require
advanced post-processing for calculation, they are often used
to describe the pharmacokinetic kinetics in a system. However,
results should be interpreted with caution. A high Cmax may either
indicate a virtually non-functioning parenchyma with arterializa-
tion caused by cirrhosis and a quick and high vascular peak, or
may reflect the excellent extraction of tracer with a high paren-
chymal signal occurring later in the study. A short T1/2 calculated
from a time-enhancement curve generated by a parenchymal ROI
is generally interpreted as good contrast agent excretion. However,
in parenchyma with no extraction capacity, in which the signal is
Table 1 Patient characteristics
Patient no. Sex Age, years MELD
score
Child–Pugh
score
Mayo
score
1 Female 61 6 6 5.2
2 Female 75 6 5 5.1
3 Female 65 6 5 5.8
4 Female 57 6 6 4.4
5 Female 71 7 5 6.0
6 Female 65 6 5 4.8
7 Female 47 11 7 6.4
8 Female 53 6 5 4.0
9 Female 71 6 6 5.6
10 Female 63 6 5 4.1
11 Male 62 14 7 7.8
12 Female 63 7 6 6.3
Control group (n = 20) M : F, 10 : 10 Median 33.5
MELD, Model for End-stage Liver Disease
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derived only from the intrahepatic blood pool, a short T1/2 will be
observed. Furthermore, a long T1/2 that would generally be inter-
preted as representing decreased liver function may be the result
of activity measured in obstructed bile ducts in a patient with
normal parenchymal function.
A weakness of this study is the low number of participating
subjects. This may have led to failure to detect actual differences
between patients and controls for some of the parameters for
which no significant differences or correlations with disease
severity were found. Furthermore, traditional confounders such
as age and gender were not controlled or corrected for. This
would have been particularly fitting as the patient group was
significantly older than the control group and the gender distri-
bution was not proportional. It could be argued that the differ-
ences described should be attributed to these baseline differences
between the groups, rather than to the diagnosis of PBC.
However, no differences were found using age and gender as
confounders in the patient and normal volunteer groups,
respectively.
The results show large ranges for both the semi-quantitative
and quantitative parameters in both patients and normal volun-
teers. As well as normal individual variation, motion artefacts and
partial volume effects may also have influenced the results. Cor-
rection for motion artefacts using image registration algorithms
before image analysis would be a logical next step in improving
the method.
Another issue pertaining to quantitative dynamic MRI that
deserves discussion is the extent of correlation between the mea-
sured signal intensity and the actual concentration of tracer in
the ROI. The logarithmic ratio described in Eq. 1 was used to
calculate relative contrast agent concentrations in the ROIs. It
has been shown that the relationship between image intensity
and Gd-DTPA concentration is non-linear for steady state MRI
pulse sequences, such as the spoiled-gradient echo sequence used
in this study.36 However, when T1 relaxation is within the
range of 40–2600 ms, the MR signal was shown to increase
approximately exponentially with shortening T1 relaxation. All
measurements were estimated to be within this range,
making Eq. 1 a good approximation to relative contrast agent
concentration.
The acquisition time in the current protocol is 90 min,
which makes the method impractical for routine clinical
use. For calculation of the DA-derived parameters, only data
from the first 30 min of each dataset are required. This would
allow the protocol to be shortened if only these parameters are
calculated.
Table 2 Segmental and global results for the quantitative parameters
Segment Global
I II III IVa IVb V VI VII VIII
Control group HEF, median 0.18 0.21 0.19 0.20 0.17 0.21 0.20 0.22 0.22 0.20
HEF, min 0.13 0.13 0.14 0.13 0.09 0.13 0.11 0.14 0.14 0.14
HEF, max 0.46 0.31 0.34 0.30 0.41 0.34 0.32 0.33 0.33 0.33
PBC group HEF, median 0.16 0.16 0.14 0.16 0.15 0.16 0.16 0.19 0.17 0.16
HEF, min 0.07 0.05 0.03 0.04 0.04 0.04 0.04 0.04 0.03 0.04
HEF, max 0.30 0.30 0.30 0.30 0.22 0.29 0.24 0.22 0.36 0.30
P-valuea 0.139 0.010 0.067 0.073 0.111 0.013 0.022 0.043 0.047 0.022
Control group irBF, median 0.26 0.22 0.23 0.22 0.22 0.25 0.27 0.26 0.25 0.24
irBF, min 0.14 0.17 0.14 0.17 0.15 0.20 0.19 0.19 0.17 0.19
irBF, max 0.33 0.29 0.30 0.32 0.32 0.32 0.33 0.32 0.32 0.31
PBC group irBF, median 0.27 0.23 0.23 0.25 0.25 0.28 0.28 0.28 0.25 0.25
irBF, min 0.19 0.17 0.15 0.23 0.23 0.21 0.21 0.21 0.18 0.22
irBF, max 0.32 0.30 0.30 0.36 0.38 0.40 0.40 0.31 0.36 0.36
P-valuea 0.586 0.199 0.613 0.027 0.080 0.371 0.312 0.756 0.312 0.350
Control group MTT, median 486 562 494 485 524 521 509 479 536 503
MTT, min 289 316 251 261 248 307 287 325 295 299
MTT, max 1629 1485 1642 1637 1589 1688 1519 1383 1723 1536
PBC group MTT, median 368 351 393 369 369 379 350 399 350 363
MTT, min 158 113 131 130 134 156 186 197 129 134
MTT, max 817 734 1976 673 766 818 754 681 864 754
P-valuea 0.057 0.011 0.161 0.047 0.020 0.052 0.036 0.102 0.027 0.029
aMann–Whitney U-test
PBC, primary biliary cirrhosis; HEF, hepatic extraction fraction; irBF, input-relative blood flow; MTT, mean transit time
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Table 3 Segmental and global results for the semi-quantitative parameters
Segment Global
I II II IVa IVb V VI VII VIII
Control
group
Cmax, median 0.533 0.473 0.451 0.459 0.448 0.574 0.574 0.557 0.553 0.537
Cmax, min 0.429 0.400 0.371 0.354 0.326 0.441 0.440 0.462 0.469 0.429
Cmax, max 0.661 0.600 0.621 0.625 0.618 0.711 0.680 0.642 0.663 0.625
PBC group Cmax, median 0.581 0.480 0.455 0.539 0.526 0.600 0.611 0.607 0.555 0.570
Cmax, min 0.276 0.269 0.288 0.324 0.324 0.376 0.319 0.319 0.360 0.319
Cmax, max 0.723 0.627 0.604 0.590 0.631 0.733 0.754 0.669 0.640 0.640
P-valuea 0.414 0.613 0.785 0.331 0.120 0.846 0.436 0.350 0.697 0.640
Control
group
Tmax, median 1500 1950 1800 1230 1800 2100 2100 1950 2130 1950
Tmax, min 840 720 840 780 960 1020 1080 960 960 1080
Tmax, max 3000 3000 3000 5400 3300 3300 3300 3300 5400 2700
PBC
group
Tmax, median 2400 1800 2400 2250 2550 2550 2550 2700 2100 2250
Tmax, min 840 120 120 120 120 120 120 120 120 120
Tmax, max 5400 3000 5400 5400 5400 5400 4800 4800 5400 5400
P-valuea 0.014 0.683 0.080 0.243 0.067 0.284 0.267 0.251 0.800 0.161
Control
group
T1/2, median 12 591 12 858 11 298 15 491 14 018 20 609 18 595 20 755 23 387 17 697
T1/2, min 2472 2439 2151 2321 1917 6222 3233 6197 6161 6161
T1/2, max 39 637 139 412 76 556 50 305 105 250 489 323 140 694 68 439 208 934 45 599
PBC
group
T1/2, median 13 305 15 898 9062 13 162 11 902 13 019 22 738 15 889 10 773 14 133
T1/2, min 3640 2367 1869 3496 2293 3262 4235 3657 3479 4704
T1/2, max 291 249 109 297 149 489 455 857 91 156 29 255 60 905 60 202 54 732 41 993
P-valuea 0.567 0.815 0.628 0.477 0.960 0.027 0.508 0.565 0.043 0.414
aMann–Whitney U-test
PBC, primary biliary cirrhosis; Cmax, maximum signal intensity; Tmax, time to maximum relative signal intensity; T1/2, time to a 50% decline in signal enhancement
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Figure 1 (A) Hepatic extraction fraction (HEF) and (B) mean transit time (MTT) plotted as a function of Model for End-stage Liver Disease
(MELD) score, showing a significant trend for decreasing parameter values with increasing disease severity
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Figure 2 (A) Hepatic extraction fraction (HEF) and (B) mean transit time (MTT) plotted as a function of Child–Pugh score, showing a significant
trend for decreasing parameter values with increasing disease severity
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Figure 3 (A) Hepatic extraction fraction (HEF) and (B) mean transit time (MTT) plotted as a function of Mayo risk score, showing a weak
negative, non-significant correlation
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The technique described may aid in the management of
patients with PBC. Percutaneous liver biopsy still has clinical
relevance, although it is not required for definitive diagnosis.
DHCE-MRI results can direct biopsies to the most affected parts
of the liver, making them more representative. The effect of new
therapies can be evaluated by comparing pre- and post-treatment
results.
From a surgical perspective, the further development of the
method may contribute to better preoperative functional analysis
of patients considered for liver resection. Current tests assess
global liver function and may fail to detect eventual segmental
dysfunction. They may also lead to the inaccurate prediction of
postoperative function as they do not account for regional differ-
ences in function. As the parametric images in Fig. 4 show, the
functional parameters can be derived on a voxel level. If the func-
tional parameter values of all voxels in a segment are added, a
quantitative assessment of the functional volume of the segment
can be derived. This will enable a much more accurate estimate of
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Figure 4 Parametric images of hepatic extraction fraction, input-relative blood flow and mean transit time in one slice of liver calculated for
(A) one healthy volunteer and (B) one patient with primary biliary cirrhosis and obvious radiological signs of cirrhosis. All parameters were
calculated on a voxel level
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the functional capacity of the future remnant liver in patients
undergoing liver surgery.
In summary, this study describes an MRI-based liver func-
tion test. In patients with PBC, the model-free parameters can
quantitatively assess hepatic function and correlates with disease
severity.
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